ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc.

April 05, 2011 14:51 ET

ProMetic Enters Into Global Agreement With Celgene Corporation

MONTREAL, QUEBEC, CANADA--(Marketwire - April 5, 2011) - ProMetic Life Sciences Inc. (TSX:PLI)("ProMetic") today announced that it had entered into an Agreement ("Agreement") with Celgene Corporation ("Celgene"), for the worldwide rights to a commercial application of ProMetic's Protein Technologies.

Under the terms of this Agreement, Abraxis BioScience, Inc. ("Abraxis"), a wholly owned subsidiary of Celgene will forgive a US$10M long-term debt entered into with ProMetic on February 9, 2010, effectively terminating said loan agreement four years prior to its original term in return for intellectual property rights for specific commercial application of its Protein Technologies within restricted fields of use.

"We are extremely pleased in Celgene's recognition of the inherent value for the commercial application of ProMetic's Protein Technologies," stated Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer. Mr. Laurin continued: "This is a win-win transaction for both parties and an efficient way of reducing a very significant portion of ProMetic's debt in a manner that is non-dilutive to our existing shareholders".

This Agreement is subject to certain conditions relating to the completion of relevant intellectual property transfer documentation. 

About Celgene Corporation 

Celgene Corporation ("Celgene"), headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") ( is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montréal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 23 of ProMetic's Annual Information Form for the year ended December 31, 2010, under the heading "Risk and Uncertainties related to ProMetic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

Contact Information

  • ProMetic Life Sciences Inc.
    Pierre Laurin
    President and CEO
    ProMetic Life Sciences Inc.
    Anne Leduc
    Manager, Investor Relations & Communications